Relief Therapeutics and NeuroX have agreed to a business combination that will create a leading digital neurotherapeutics firm, pending closure in December 2025.

Target Company Overview

Relief Therapeutics Holding SA, a biopharmaceutical company headquartered in Geneva, focuses on developing innovative treatments for rare diseases. With expertise in drug delivery systems and repurposing, Relief’s clinical pipeline incorporates therapies aimed at addressing critical unmet medical needs across various conditions, including dermatological, metabolic, and respiratory disorders. The firm is publicly traded on the SIX Swiss Exchange.

Industry Overview in Switzerland

Switzerland's biopharmaceutical sector is characterized by a strong emphasis on research and innovation, bolstered by robust governmental support and regulatory frameworks. The country is home to several leading pharmaceutical companies and attracts substantial foreign investments thanks to its skilled workforce and advanced infrastructure. Furthermore, the nation's strategic location in Europe provides access to significant markets.

In recent years, there has been an increasing demand for specialized medicines, particularly in rare diseases. This growing market is fueled by advancements in technology alongs